Novo Nordisk's next-gen obesity drug Cagrisema
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...
Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new ...
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering ...
Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug, amycretin. Warning!
Here are some of the major companies whose stocks moved on the week’s news.
the Danish pharmaceutical company experienced a 21% plunge in its share price following disappointing trial results for its new obesity drug, CagriSema. Amycretin is considered as Novo ...
Novo Nordisk shares rose sharply Friday ... on concerns it will have to cut the price of its drugs in the U.S. The company behind blockbuster obesity treatment Wegovy and diabetes drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback